Premium
P‐glycoprotein Interactions of Nefazodone and Trazodone in Cell Culture
Author(s) -
Störmer Elke,
Moltke Lisa L.,
Perloff Michael D.,
Greenblatt David J.
Publication year - 2001
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912700122010609
Subject(s) - p glycoprotein , chemistry , pharmacology , caco 2 , bioavailability , in vivo , transporter , cell culture , cell , biochemistry , medicine , biology , multiple drug resistance , genetics , microbiology and biotechnology , gene , antibiotics
This study investigated the effects of nefazodone (NFZ) and trazodone (TZD) on P‐glycoprotein (P‐gp) activity and expression in cell culture. NFZ and TZD showed no differential transport between the basolateral to apical and apical to basolateral direction across Caco‐2 cell monolayers. Transport in either direction was not affected by verapamil. NFZ was a potent inhibitor (IC 50 = 4.7 M) of rhodamine123 (Rh123)B to A transport across Caco‐2 cell monolayers, while TZD had minimal effect. Following 72‐hour exposure of LS180V cells to NFZ and TZD (10 M), a twofold increase in immunoreactive P‐gp was observed. Rh123 accumulation into these cells was reduced to 65% and 74% of control by NFZ and TZD (10 M), respectively. It was concluded that differential rates of transport of NFZ and TZD in Caco‐2 cells were not evident. However, NFZ is an inhibitor of P‐gp activity at clinically relevant in vivo concentrations and may have the potential to increase bioavailability of coadministered compounds that are substrates for transport. Concentrations of NFZ and TZD achieved in the intestine after chronic oral dosing may induce P‐gp expression and reduce absorption of coadministered drugs.